| 000 | 01857 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250515183335.0 | ||
| 264 | 0 | _c20100330 | |
| 008 | 201003s 0 0 eng d | ||
| 022 | _a1522-9645 | ||
| 024 | 7 |
_a10.1093/eurheartj/ehp318 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLip, Gregory Y H | |
| 245 | 0 | 0 |
_aOral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. _h[electronic resource] |
| 260 |
_bEuropean heart journal _cDec 2009 |
||
| 300 |
_a2897-907 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAnticoagulants _xtherapeutic use |
| 650 | 0 | 4 |
_aAntifibrinolytic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aAtrial Fibrillation _xcomplications |
| 650 | 0 | 4 |
_aBiomarkers _xmetabolism |
| 650 | 0 | 4 | _aBleeding Time |
| 650 | 0 | 4 |
_aEmbolism _xprevention & control |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFibrin Fibrinogen Degradation Products _xmetabolism |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aStroke _xprevention & control |
| 650 | 0 | 4 |
_aThrombin _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aVitamin K _xantagonists & inhibitors |
| 700 | 1 | _aRasmussen, Lars H | |
| 700 | 1 | _aOlsson, S Bertil | |
| 700 | 1 | _aJensen, Eva C | |
| 700 | 1 | _aPersson, Anders L | |
| 700 | 1 | _aEriksson, Ulf | |
| 700 | 1 | _aWåhlander, Karin F C | |
| 773 | 0 |
_tEuropean heart journal _gvol. 30 _gno. 23 _gp. 2897-907 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/eurheartj/ehp318 _zAvailable from publisher's website |
| 999 |
_c19093142 _d19093142 |
||